PerkinElmer
check quantity

Anti-DIG Alpha Donor beads, 1 mg

Alpha Donor beads conjugated to anti-DIG (digoxin) antibody. This bead can be used to capture Dig-labeled biomolecules for Alpha no-wash assays.

For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).

Part Number
Unit Size
List Price
Your Price
Quantity
AS108D
1 mg
644.00 USD
 
more
AS108M
5 mg
2516.00 USD
 
more
AS108R
25 mg
10900.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Alpha Donor beads conjugated to anti-Digoxin antibody. Anti-Dig beads are a good alternative to streptavidin Donor beads for assays where biotin in samples (e.g., culture media) might interfere. These beads can be used to capture Dig-labeled antibodies, proteins and peptides, and can be used in conjunction with AlphaScreen, AlphaLISA, or AlphaPlex Acceptor beads to create no-wash assays for:

  • Analyte detection assays
  • Protein-protein interaction assays
  • Protein-DNA interaction assays
  • Protein-RNA interaction assays
  • Protein-small molecule interaction assays
  • Protein detection assays
  • Enzymatic assays

In a typical Alpha assay, 1 mg of beads is sufficient to run 1,000-2,000 wells using a 25 µL reaction volume. Bead concentration can be adjusted for optimal performance.

Specifications

Antibody Conjugates Anti-DIG
Automation Compatible Yes
Bead Type or Core Bead Type Alpha Donor
Product Brand Name AlphaLISA
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Unit Size 1 mg
Resources, Events & More
  • All

Application Brief

Eight Limitations of ELISA and How to Overcome Them Using Alternative Technologies

The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.

Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.

PDF 1 MB

Application Note

Development of Pharmacokinetic (PK) Assays for Detecting Biosimilars Targeting TNF alpha using AlphaLISA

Anti-inflammatory monoclonal antibody drugs that specifically target TNFα, such as Humira®, have been highly successful in the market. As patents expire on these top-selling drugs, effort has been placed on developing biosimilars. Biosimilars differ from small molecule generic drugs in that their chemical structure does not have to be exactly the same as the patented drug. Therefore, the FDA has stringent requirements for proving that the biosimilars have the same efficacy and safety profile as the patented drug. Companies that develop biosimilars are tasked with proving that the biosimilar shows equivalent pharmacokinetics as the patented drug.

Proving “biosimilarity” involves comparing parameters such as overall exposure, absorption, half-life, and clearance time using patient samples. Sensitive, robust, and fast assays are needed to measure these parameters. Traditional methods for detecting and quantifying these drugs in patient samples include time-consuming, wash-based ELISA and MSD methods. In contrast, AlphaLISA allows for fast, no-wash, high-throughput detection and quantification of the drug of interest in a variety of sample matrices. Here, we demonstrate the application of AlphaLISA for detecting biosimilars targeting TNFα.

PDF 2 MB

Brochure

Guide

Alpha Protein-Protein Interaction Quick Start Guide

Alpha has been used to study a wide variety of interactions, including protein:protein, protein:peptide, protein:DNA, protein:RNA, protein:carbohydrate, protein:small molecule, receptor:ligand, and nuclear receptor:ligand interactions. Both cell-based and biochemical interactions have been monitored, and applications such as phage display, ELISA, and EMSA (electrophoretic mobility shift assay) have been adapted to Alpha.

PDF 380 KB
ELISA to AlphaLISA Immunoassay Conversion Guide

This guide presents the simple conversion of an ELISA or other immunoassay to an AlphaLISA® immunoassay.

PDF 1 MB
User's Guide To Alpha Assays Protein:Protein Interactions

AlphaScreen® and AlphaLISA® are bead-based assay technologies used to study biomolecular interactions in a microplate format. The acronym “Alpha” stands for Amplified Luminescent Proximity Homogeneous Assay. The assay does not require any washing steps. Binding of proteins or other binding partners captured on the beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent signal.

PDF 2 MB

Technical Note

Development of an AlphaLISA Assay to Measure and Screen Inhibitors of the p53-MDM2 Interaction

Binding events between biomolecules are important components of biological processes and a number of these biomolecular interactions have been targeted for the development of novel therapeutic drugs. p53 is a transcription factor and tumor suppressor protein that is activated in response to cellular stress, and MDM2 was identified as a negative regulator that binds to p53 and tags it for ubiquitination and subsequent degradation.

The p53-MDM2 protein-protein interaction has been an excellent target for therapeutic drugs and therefore makes a good model system for developing an AlphaLISA assay to screen for inhibitors of the interaction. In this technical note, we show how to develop an assay to screen for inhibitors and how to measure a dissociation constant for moderate binding protein-protein interaction using AlphaLISA®.

PDF 1 MB